"Cardiotonic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).
| Descriptor ID |
D002316
|
| MeSH Number(s) |
D27.505.954.411.222 D27.720.799.080
|
| Concept/Terms |
Cardiotonic Agents- Cardiotonic Agents
- Cardiac Stimulants
- Inotropic Agents, Positive Cardiac
- Cardiotonic Drugs
- Cardiotonics
- Myocardial Stimulants
- Cardioprotective Agents
|
Below are MeSH descriptors whose meaning is more general than "Cardiotonic Agents".
Below are MeSH descriptors whose meaning is more specific than "Cardiotonic Agents".
This graph shows the total number of publications written about "Cardiotonic Agents" by people in this website by year, and whether "Cardiotonic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 1 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 2 | 0 | 2 |
| 2012 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 2 | 3 |
| 2015 | 0 | 1 | 1 |
| 2017 | 30 | 16 | 46 |
| 2018 | 27 | 18 | 45 |
| 2019 | 6 | 8 | 14 |
| 2020 | 1 | 9 | 10 |
| 2021 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Cardiotonic Agents" by people in Profiles.
-
Endothelial Dysfunction as a Component of Severe Acute Respiratory Syndrome Coronavirus 2-Related Multisystem Inflammatory Syndrome in Children With Shock. Crit Care Med. 2021 11 01; 49(11):e1151-e1156.
-
Covid-19 and development of heart failure: mystery and truth. Naunyn Schmiedebergs Arch Pharmacol. 2021 10; 394(10):2013-2021.
-
The potential role of thymoquinone in preventing the cardiovascular complications of COVID-19. Vascul Pharmacol. 2021 12; 141:106899.
-
BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. Cell. 2021 04 15; 184(8):2167-2182.e22.
-
COVID-19 and cardiovascular complications: an update from the underlying mechanism to consequences and possible clinical intervention. Expert Rev Anti Infect Ther. 2021 09; 19(9):1083-1092.
-
Outcome of Children Admitted With SARS-CoV-2 Infection: Experiences From a Pediatric Public Hospital. Indian Pediatr. 2021 04 15; 58(4):358-362.
-
Impact of COVID-19 on patients with congenital heart disease. Cardiol Young. 2021 01; 31(1):163-165.
-
Cardiometabolic vigilance in COVID-19 and resource husbandry in resource-challenged times: Clinical practice- based expert opinion. Diabetes Metab Syndr. 2021 Jan-Feb; 15(1):55-62.
-
Is there an association between metformin use and clinical outcomes in diabetes patients with COVID-19? Diabetes Metab. 2021 07; 47(4):101208.
-
SARS-CoV-2 infection in an infant with severe dilated cardiomyopathy. Cardiol Young. 2021 Mar; 31(3):485-487.